Use search to browse all 100+ peptides
GHRH (1-29), GRF 1-29 NH2, Sermorelin acetate
A synthetic 29-amino acid analog of growth hormone-releasing hormone that stimulates pituitary gland to release growth hormone.
Guo. Jian J; Schally. Andrew V AV; Zarandi. Marta M; Varga. Jozsef J; Leung. Peter C K PC
A lab study found that a synthetic growth‑hormone‑releasing‑hormone blocker called JMR‑132 can slow the growth of ovarian‑cancer cells in a dish by messing with the EGFR‑Akt signaling pathway, but this work is only in cell cultures and not in people.
Papadia. A A; Schally. A V AV; Halmos. G G; Varga. J L JL; Seitz. S S; Buchholz. S S; Rick. F F; Zar...
Researchers found that drugs blocking the hormone that normally tells the body to release growth hormone can slow the growth of ovarian cancer cells in lab dishes and in mice, but this work is early‑stage and doesn’t tell you how to use sermorelin or similar peptides for health or performance.
Pozsgai. Eva E; Schally. Andrew V AV; Hocsak. Eniko E; Zarandi. Marta M; Rick. Ferenc F; Bellyei. Sz...
This lab study tested a new drug that blocks growth‑hormone‑releasing hormone (GHRH) and found it can kill breast‑cancer cells in a dish, even those that don’t have the usual hormone receptors. It works by shutting down cell‑survival signals and turning on stress pathways, but the work is only in cell cultures, not people.
Telegdy. Gyula G; Schally. Andrew V AV
A mouse study found that a drug blocking growth‑hormone‑releasing hormone (GH‑RH) called MZ‑4‑71 reduces anxiety‑like behavior, and this effect depends on several brain receptors (adrenergic, serotonin and GABA). The drug also showed antidepressant‑like and memory‑enhancing effects, but it works by suppressing growth hormone, not by boosting it like sermorelin does.
Cen. Ling-Ping LP; Ng. Tsz Kin TK; Liang. Jia-Jian JJ; Xu. Ciyan C; Zhuang. Xi X; Liu. Yu-Fen YF; Ch...
A study in rats found that a drug that mimics growth‑hormone‑releasing hormone (called MR‑409) can help protect eye nerve cells after injury, especially when the immune system is also activated. The same drug’s blocker (MIA‑602) reduced inflammation but didn’t boost protection as much. These results are early‑stage and not ready for human use.
Wu. Hsien-Ming HM; Huang. Hong-Yuan HY; Schally. Andrew V AV; Chao. Angel A; Chou. Hung-Hsueh HH; Le...
A lab study found that blocking the hormone‑releasing signal (GHRH) can slow down the movement of endometrial cancer cells by lowering two proteins, Twist and N‑cadherin, that help cells spread. This effect only shows up in cell cultures and depends on the presence of the GHRH receptor.
Xu. Y Y; Jiang. Y F YF; Wu. B B
The paper reviews new peptide drugs being tested for advanced prostate cancer, like hormone‑blocking and hormone‑stimulating compounds, including some that act like growth‑hormone‑releasing hormone. While they can help the disease, they also cause side effects such as sexual problems, liver and kidney issues, bone loss, anemia and diarrhea. For people experimenting with health‑optimizing peptides, this study mainly warns that using similar compounds (e.g., sermorelin) could have serious risks if you have or are prone to prostate issues, and it doesn’t give any new dosing tricks for performance or longevity.
Szalontay. Luca L; Benveniste. Ronald J RJ; Schally. Andrew V AV; Vidaurre. Irving I; Nadji. Mehrdad...
The study shows that two experimental drugs that block growth‑hormone‑releasing hormone (GHRH) can stop extra GH spikes in a human pituitary tumor, but they don’t change the tumor’s normal GH output. This matters mainly for treating rare cases of excess GH, not for boosting GH in healthy people.
Liu. A-X AX; Zhang. D D; Zhu. Y-M YM; Gao. H-J HJ; Jiang. J-Y JY; Hu. X-L XL; Lv. P-P PP; Leung. P C...
The study shows that blocking the growth‑hormone‑releasing hormone receptor (GHRH‑R) in a placental cancer cell line makes the cells die faster by turning off survival signals (Akt) and causing stress in the cell’s protein‑making machinery. This is mostly a lab‑only finding and doesn’t give clear guidance for using sermorelin or similar peptides in everyday health or longevity routines.
Pont. Laura L; Alechaga. Élida É; Terrero. Alejandro A; Monfort. Núria N; Ventura. Ro...
The study describes a lab technique for spotting tiny amounts of growth‑hormone‑releasing peptides like sermorelin in urine, using special magnetic beads to pull them out before a high‑tech mass‑spectrometer reads them. It’s mainly about improving detection for anti‑doping tests, not about how to use or dose the peptides.
Otin. Joanie J; Tran. N Thuy NT; Benoit. Aurélie A; Buisson. Corinne C; Taverna. Myriam M
Scientists developed a lab test that can spot tiny amounts of growth‑hormone‑releasing peptides like sermorelin in urine. By using a special chemical and a technique that concentrates a large sample before analysis, they can detect levels as low as about 0.1 µg/mL. The method works, but it needs specialized equipment and chemicals.
Szalontay. Luca L; Schally. Andrew V AV; Popovics. Petra P; Vidaurre. Irving I; Krishan. Awtar A; Za...
A lab study tested new compounds that block the hormone that normally tells the body to release growth hormone. In skin cancer cells and mice, one of these blockers (MIA‑690) slowed tumor growth and pushed a cell‑cycle protein (p27) into the cell nucleus, which can halt cell division. The work is still early‑stage and done in animals, not people.
Köster. Frank F; Engel. Jörg B JB; Schally. Andrew V AV; Hönig. Arnd A; Schröer....
Researchers found that many triple‑negative breast cancers have receptors for the hormone‑releasing factor GHRH and that a synthetic GHRH blocker can slow the growth of these cancer cells in the lab. This suggests a possible new drug target, but it doesn't give any direct advice for everyday health or anti‑aging routines.
Zhang. Chongxu C; Cai. Renzhi R; Lazerson. Aaron A; Delcroix. Gaetan G; Wangpaichitr. Medhi M; Mirsa...
In mice, blocking the receptor for growth‑hormone‑releasing hormone (using a compound called MIA‑602) reduced lung inflammation and scarring caused by the drug bleomycin. The treatment also changed the activity of many immune‑related genes in the lungs.
Trainer. P J PJ; Palermo. M M; Kirk. J M JM; Fanciulli. G G; Perry. L H LH; Delitala. G G; Besser. G...
In a study of 40 healthy young men, researchers found that tall and short adults had almost identical growth‑hormone (GH) responses to insulin‑induced hypoglycaemia, GHRH, and during the night, and their IGF‑1 levels were the same, meaning that how much GH your body makes doesn’t decide how tall you end up as an adult.
Keller. Gunhild G; Schally. Andrew V AV; Groot. Kate K; Toller. Gabor L GL; Havt. Alexandre A; K...
In a mouse study, drugs that block the hormone that normally tells the body to release growth hormone (called GHRH antagonists) slowed the growth of two types of human lymphoma tumors by about 60‑74%. The treatment also lowered a growth‑promoting protein (IGF‑1) in the blood and reduced another factor (bFGF) inside the tumors, but didn’t affect VEGF. These findings are early‑stage and done in animals, so they don’t translate into a usable protocol for people right now.
Coppieters. Gilles G; Deventer. Koen K; Polet. Michaël M; Van Eenoo. Peter P; Judák. P...
Scientists created a cheap, antibody‑free lab test that can spot tiny amounts of growth‑hormone‑releasing peptides like sermorelin in urine. The method is sensitive, works after many samples, and costs less than traditional antibody‑based tests, but it mainly helps labs detect illegal or banned substances rather than guide how to use the peptides.
Engel. Jörg B JB; Keller. Gunhild G; Schally. Andrew V AV; Toller. Gabor L GL; Groot. Kate K; H...
A study in mice found that a drug that blocks growth‑ hormone‑releasing hormone (GHRH) can shrink human endometrial cancer tumors, but the compound used isn’t the same as the commonly used GHRH peptide sermorelin and isn’t available for personal use.
Zarandi. Marta M; Varga. Jozsef L JL; Schally. Andrew V AV; Horvath. Judit E JE; Toller. Gabor L GL;...
Scientists made new versions of a hormone‑blocking peptide by attaching fatty acids, and these modified peptides worked better at stopping cancer cells in lab dishes and slowed tumor growth in mice, but they didn’t show stronger effects on hormone release in living animals and there’s no human data yet.
Rick. Ferenc G FG; Schally. Andrew V AV; Block. Norman L NL; Abi-Chaker. Andrew A; Krishan. Awtar A;...
In rats, blocking both growth‑hormone‑releasing hormone (GHRH) and luteinizing‑hormone‑releasing hormone (LHRH) shrank the prostate by about 30%. In human prostate cell cultures, the two blockers together stopped cancer‑like cells from growing, mainly by trapping them in the DNA‑synthesis (S) phase. Normal prostate stromal cells were less affected. The study suggests this drug combo could be a new way to treat benign prostate enlargement, but it’s still early‑stage animal work.